42754-97-2

Usage

Uses

Used in Medicinal Chemistry:
6-Chloro-1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its ability to participate in diverse chemical reactions allows for the formation of a wide range of derivatives with potential biological activities, making it a valuable component in the development of new drugs.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 6-Chloro-1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one serves as a starting material for the design and synthesis of novel therapeutic agents. Its unique structural features and potential to form biologically active derivatives contribute to the exploration of new treatment options for various diseases and conditions.
Used in Drug Discovery:
6-Chloro-1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one is employed as a target molecule in drug discovery processes. Its unique properties and potential to form derivatives with pharmacological activities make it an interesting subject for further research and development, with the aim of identifying new drug candidates with improved efficacy and safety profiles.
Used in Drug Development:
In the drug development field, 6-Chloro-1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one is used as a building block for the creation of innovative pharmaceutical formulations. Its versatility in chemical reactions and potential to generate biologically active compounds contribute to the advancement of new drug therapies and the improvement of existing ones.
Used in Chemical Synthesis:
6-Chloro-1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one is utilized as a versatile reagent in chemical synthesis processes. Its ability to form a wide range of derivatives with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science, highlights its importance as a synthetic building block.
Used in Research and Development:
6-Chloro-1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one is employed as a subject of research and development in various scientific fields. Its unique structural features and potential applications in medicinal chemistry and pharmaceutical research make it an attractive target for further exploration and innovation, with the aim of discovering new applications and improving existing ones.

InChI:InChI=1/C5H3ClN4O/c6-5-8-3-2(1-7-10-3)4(11)9-5/h1H,(H2,7,8,9,10,11)

Upstream product

• 42754-96-1 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine 
• 2465-59-0 oxypurinol 

Downstream Products

• 24521-76-4 6-thioxo-1,5,6,7-tetrahydropyrazolo<3,4-d>pyrimidin-4-one 
• 2537-04-4 6-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 

Relevant academic research and scientific papers

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) plays a role in receptor tyrosine kinase (RTK), neurofibromin-1 (NF-1), and Kirsten rat sarcoma virus (KRAS) mutant-driven cancers, as well as in RTK-mediated resistance, making the identification of small-molecule therapeutics that interfere with its function of high interest. Our quest to identify potent, orally bioavailable, and safe SHP2 inhibitors led to the discovery of a promising series of pyrazolopyrimidinones that displayed excellent potency but had a suboptimal in vivo pharmacokinetic (PK) profile. Hypothesis-driven scaffold optimization led us to a series of pyrazolopyrazines with excellent PK properties across species but a narrow human Ether-à-go-go-Related Gene (hERG) window. Subsequent optimization of properties led to the discovery of the pyrimidinone series, in which multiple members possessed excellent potency, optimal in vivo PK across species, and no off-target activities including no hERG liability up to 100 μM. Importantly, compound 30 (IACS-15414) potently suppressed the mitogen-activated protein kinase (MAPK) pathway signaling and tumor growth in RTK-activated and KRASmut xenograft models in vivo.

HETEROCYCLIC INHIBITORS OF PTPN11

The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. The compounds are based on various substituted ring-fused pyrimidin-4-ones.

HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS

Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.

PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE

There are provided compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein Q, R1 and R2 are as defined herein. The compounds of formula I are useful in the treatment of cancer.